Gastrointestinal stromal tumor MRI: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(13 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Gastrointestinal stromal tumor}}
{{Gastrointestinal stromal tumor}}
{{CMG}}{{AE}}{{PSD}}
{{CMG}}{{AE}}{{Akshun}}


==Overview==
==Overview==
MRI scan may be helpful in the diagnosis of gastrointestinal stromal tumor.
[[MRI]] is more accurate and sensitive than a [[CT scan]] for delineating [[rectal]] gastrointestinal stromal tumors (GISTs). For GISTs located at other locations [[MRI]] is as sensitive as a [[CT scan]]. However, a [[biopsy]] ([[Endoscopy|endoscopic]] or [[CT]] guided) is the [[Gold standard (test)|gold standard]] in diagnosing GIST. On a T1 weighted [[Magnetic resonance imaging|MRI]], low signal [[intensity]] indicates solid component GIST whereas on a T2 weighted [[Magnetic resonance imaging|MRI]], high signal [[intensity]] indicates solid component GISTs.


==MRI==
==MRI==
Presence of necrosis, haemorrhagic and cystic change make appearances variable:
[[MRI]] is more accurate and sensitive than a [[CT scan]] for delineating rectal gastrointestinal stromal tumors (GISTs). For GISTs located at other locations [[MRI]] is as sensitive as a [[CT scan]].<ref name="pmid15648083">{{cite journal |vauthors=Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, Sablinska K, Kindblom LG |title=Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden |journal=Cancer |volume=103 |issue=4 |pages=821–9 |year=2005 |pmid=15648083 |doi=10.1002/cncr.20862 |url=}}</ref><ref name="pmid14645423">{{cite journal |vauthors=Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA |title=Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor |journal=J. Clin. Oncol. |volume=21 |issue=23 |pages=4342–9 |year=2003 |pmid=14645423 |doi=10.1200/JCO.2003.04.190 |url=}}</ref>
*T1:
*[[MRI]] is more sensitive in identifying GIST associated [[hemorrhage]], [[necrosis]], surrounding structures and [[metastasis]].
:*Low signal intensity solid component
* On an [[MRI]], the presence of [[hemorrhage]], [[necrosis]] and cystic change may have variable appearance:
:*Enhancement is usually present, and predominantly peripheral in larger lesions
**On a T1 weighted [[Magnetic resonance imaging|MRI]]:
 
***Low signal [[Intensity (physics)|intensity]] indicates solid component GISTs.
*T2: high signal intensity solid component
***With larger GISTs, contrast induced enhancement is present and predominantly peripheral in larger [[Lesion|lesions]] (>10 cms).
 
**On a T2 weighted [[Magnetic resonance imaging|MRI]]
 
*** High signal intensity indicates solid component GISTs.


==References==
==References==
Line 26: Line 26:
{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]
[[Category:Gastroenterology]]
[[Category:Surgery]]

Latest revision as of 03:43, 4 March 2019

Gastrointestinal stromal tumor Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Screening

Differentiating Gastrointestinal stromal tumor from other Diseases

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Gastrointestinal stromal tumor MRI On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Gastrointestinal stromal tumor MRI

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Gastrointestinal stromal tumor MRI

CDC on Gastrointestinal stromal tumor MRI

Gastrointestinal stromal tumor MRI in the news

Blogs on Gastrointestinal stromal tumor MRI

Directions to Hospitals Treating Gastrointestinal stromal tumor

Risk calculators and risk factors for Gastrointestinal stromal tumor MRI

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

MRI is more accurate and sensitive than a CT scan for delineating rectal gastrointestinal stromal tumors (GISTs). For GISTs located at other locations MRI is as sensitive as a CT scan. However, a biopsy (endoscopic or CT guided) is the gold standard in diagnosing GIST. On a T1 weighted MRI, low signal intensity indicates solid component GIST whereas on a T2 weighted MRI, high signal intensity indicates solid component GISTs.

MRI

MRI is more accurate and sensitive than a CT scan for delineating rectal gastrointestinal stromal tumors (GISTs). For GISTs located at other locations MRI is as sensitive as a CT scan.[1][2]

  • MRI is more sensitive in identifying GIST associated hemorrhage, necrosis, surrounding structures and metastasis.
  • On an MRI, the presence of hemorrhage, necrosis and cystic change may have variable appearance:
    • On a T1 weighted MRI:
      • Low signal intensity indicates solid component GISTs.
      • With larger GISTs, contrast induced enhancement is present and predominantly peripheral in larger lesions (>10 cms).
    • On a T2 weighted MRI
      • High signal intensity indicates solid component GISTs.

References

  1. Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, Sablinska K, Kindblom LG (2005). "Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden". Cancer. 103 (4): 821–9. doi:10.1002/cncr.20862. PMID 15648083.
  2. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA (2003). "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor". J. Clin. Oncol. 21 (23): 4342–9. doi:10.1200/JCO.2003.04.190. PMID 14645423.


Template:WikiDoc Sources